23andMe Board Rejects CEO Anne Wojcicki’s Lowball Buyout Offer, Raising Big Questions for Investors

The Special Committee of the Board of Directors of 23andMe Holding Co. (“23andMe” or the “Company”) (Nasdaq: ME) today confirmed ...

March 04, 2025 | Tuesday | Analysis
LSPedia Secures MMCAP Infuse DSCSA Compliance Contract to Expand U.S. Reach

LSPedia, a global leader in pharmaceutical traceability and supply chain SaaS solutions, has secured its second major U.S. government contract, the MMCAP I...

February 27, 2025 | Thursday | News
Biogen and Stoke Therapeutics Collaborate on Zorevunersen for Dravet Syndrome Treatment

Biogen Inc.  and Stoke Therapeutics, Inc. announced a collaboration for the development and commercialization of zorevunersen, a potential f...

February 19, 2025 | Wednesday | News
Alumis and ACELYRIN Announce Definitive Merger Agreement, Creating a Leading Immunology Biopharma with Late-Stage Pipeline Strength

Alumis Inc. (Nasdaq: ALMS) and ACELYRIN, Inc. (Nasdaq: SLRN) today announced a definitive merger agreement, creating a powerhouse in immunology-focused b...

February 07, 2025 | Friday | News
BD Announces Strategic Plan to Separate Biosciences and Diagnostic Solutions Business to Unlock Value for Shareholders

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced its board of directors has unanimously authoriz...

February 06, 2025 | Thursday | News
Disc Medicine Announces Upsized $225.5 Million Public Offering of Common Stock and Pre-Funded Warrants

Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...

January 23, 2025 | Thursday | News
Ocular Therapeutix Grants Inducement Awards to New Employee Under 2019 Stock Incentive Plan

Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to redefining the retina ex...

January 20, 2025 | Monday | News
Silexion Therapeutics Prices Public Offering to Raise $5 Million for RNAi Cancer Therapy Development

Silexion Therapeutics Corp (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA inter...

January 16, 2025 | Thursday | News
TC BioPharm Shareholders Approve 25% Stock Dividend, Reinforcing Strong Financial Outlook

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic ...

January 07, 2025 | Tuesday | News
Spyre Therapeutics Grants Stock Options to Non-Executive Employee as Part of Equity Inducement Award

Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineerin...

January 06, 2025 | Monday | News
Innocan Pharma Successfully Completes Non-Brokered Private Placement, Raising $635,444.60 to Advance CBD-Loaded Liposome Platform

Innocan Pharma Corporation (the "Company") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has closed its previously announced no...

January 01, 2025 | Wednesday | News
Former Humanigen CSO Dale Chappell Indicted for Insider Trading Scheme Avoiding $38M in Losses

An indictment unsealed on charged the former chief scientific officer of biopharmaceutical company Humanigen (0KB2.BE), opens new tab with engagi...

December 30, 2024 | Monday | News
Catalent’s $16.5 Billion Acquisition by Novo Holdings Sets the Stage for Transforming Global Healthcare

Catalent, Inc. (“Catalent”), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S...

December 19, 2024 | Thursday | News
bluebird bio Announces 1-for-20 Reverse Stock Split to Regain Nasdaq Listing Compliance

bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) announced that it will proceed with a 1-for-20 reverse stock sp...

December 09, 2024 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close